NEW YORK, Aug. 30, 2017 /PRNewswire/ -- Plaintiffs who allegedly developed gynecomastia due to treatment with Risperdal continue to file claims in the Pennsylvania mass tort program currently underway in the Philadelphia Court of Common Pleas. According to the Court's website, at least 6,082 Risperdal lawsuits are now pending in the proceeding, up from 5,548 cases in early June. (Case No. 130600861)
The Risperdal mass tort program continues to move forward, with the Court set to convene its next meeting on Wednesday, September 13, 2017, at 3:00 p.m.
"Our Firm is representing a number of plaintiffs who allegedly experienced excessive male breast growth as a result of Risperdal treatment, and we continue to receive inquiries from potential plaintiffs on a regular basis. We look forward to next month's meeting in Philadelphia, and will monitor the proceeding for any developments that could impact our clients' claims," said Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to provide free legal reviews to men and boys who were diagnosed with gynecomastia allegedly related to their use of Risperdal.
Risperdal and Gynecomastia
Risperdal is an atypical antipsychotic medication indicated for use in adult and adolescent patients with schizophrenia, adults and children ages 10-to-17 with bipolar disorder, and children (5-to-16 years of age) with autistic disorder. The U.S. Food & Drug Administration (FDA) granted initial approval for Risperdal in 1993. However, its first pediatric indications were not approved until October 2006.
The Risperdal label was also updated in October 2006 to state that 2.3% of male adolescents treated with Risperdal had developed gynecomastia. Previously, the label characterized excessive male breast growth as a rare side effect that had been seen in fewer than 1 in 1,000 patients.
Johnson & Johnson and its Janssen Pharmaceuticals unit are accused of failing to warn doctors and patients about the association between Risperdal and gynecomastia. Plaintiffs also allege that the companies aggressively marketed Risperdal for use in children long before the FDA cleared the drug for pediatric indications.
The Pennsylvania litigation has been trying Risperdal gynecomastia lawsuits since February 2015. So far, four of those trials have concluded with verdicts in favor of plaintiffs, with damage awards ranging from $500,000 to $70 million.
Bernstein Liebhard LLP continues to provide free legal reviews to alleged victims of Risperdal and gynecomastia. To learn more about filing a Risperdal lawsuit, please contact Bernstein Liebhard LLP by visiting the Firm's website, or by calling 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
View original content:http://www.prnewswire.com/news-releases/risperdal-lawsuit-filings-exceed-6000-in-pennsylvania-mass-tort-as-court-prepares-to-convene-september-meeting-bernstein-liebhard-llp-reports-300511707.html
SOURCE Bernstein Liebhard LLP